written on 29.09.2020

Two start-ups from Western Switzerland revolutionize the treatment of glaucoma

TAGS: ,

Rheon Medical is revolutionizing glaucoma treatment with its eyeWatch system, in which Coat-X’s coating technology plays a central role. Both start-ups were awarded prizes at the 2020 edition of the Swiss Medtech Day.

On the occasion of the most important event in the Swiss medical technology sector, the Swiss Medtech Day, the two Western Switzerland-based start-ups Rheon Medical and Coat-X received the Swiss Medtech Award in the amount of CHF 50,000.

Glaucoma is an eye disease that irreversibly damages the optic nerve. Excessive intraocular pressure is the greatest risk factor for the development of glaucoma. With the eyeWatch solution from Rheon Medical, a start-up based in Lausanne in the canton of Vaud, the patient’s intraocular pressure can be easily adjusted or set as needed.

Thanks to the innovative coating technology from Coat-X, a start-up based in the canton of Neuchâtel, the magnetic plate is protected against erosion caused by bodily fluids, a prerequisite for the implantation of the eyeWatch system.

A country and region among the most attractive for the development and manufacturing of complex and innovative devices

“Switzerland is one of the most attractive locations in the world for the development and manufacturing of complex and innovative medical devices. The joint performance of the two companies Rheon Medical and Coat-X, which received an award today, is an excellent example of this – an ideal interaction between engineering, microtechnology and materials technology,” said Peter Biedermann, Director of Swiss Medtech.

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here